SCHEMBL19731939

SCHEMBL19731939

COc1ccc(-n2nc(O)cc2NC(=O)Nc2ccc(Oc3ccnc(NC(=O)NC4CC4)c3)c(Cl)c2Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 10/20 0.51
MAPK14 Q16539 7/20 0.51
MAPK12 P53778 7/20 0.51
HCK P08631 2/20 0.51
GSK3A P49840 10/20 0.45
SYK P43405 9/20 0.45
GSK3B P49841 1/20 0.44
RIPK2 O43353 1/20 0.43
ERN1 O75460 1/20 0.43
STK10 O94804 1/20 0.43
MAP3K6 O95382 1/20 0.43
ABL1 P00519 1/20 0.43
ESR1 P03372 1/20 0.43
RET P07949 1/20 0.43
PDGFRB P09619 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
KIT P10721 1/20 0.43
BCR P11274 1/20 0.43
FGFR1 P11362 1/20 0.43
NQO2 P16083 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19732043 0.92 MAPK14 (0.43) SRCMAPK14MAPK12HCKGSK3A
SCHEMBL14656162 0.91 MAPK14 (0.64) SRCMAPK14MAPK12HCKGSK3A
SCHEMBL19732003 0.91 MAPK12 (0.43) SRCMAPK14MAPK12HCKGSK3A
SCHEMBL19388857 0.90 SRC (0.54) SRCMAPK14MAPK12HCKGSK3A
SCHEMBL19388733 0.88 SRC (0.47) SRCMAPK14MAPK12HCKGSK3A
SCHEMBL19732072 0.88 SRC (0.52) SRCMAPK14MAPK12HCKGSK3A
SCHEMBL19732005 0.87 SRC (0.53) SRCMAPK14MAPK12HCKGSK3A
SCHEMBL19732100 0.87 SRC (0.51) SRCMAPK14MAPK12HCKGSK3A
SCHEMBL19731957 0.87 SRC (0.51) SRCMAPK14MAPK12HCKGSK3A
SCHEMBL19731935 0.87 MAPK14 (0.59) SRCMAPK14MAPK12HCKGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000471-B2 Pyrazole P38 map kinase inhibitors RESPIVERT LIMITED (GB) 2018-06-19 US disclosed
US-20170362208-A1 NOVEL COMPOUNDS RESPIVERT LIMITED (GB) 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362208-A1 NOVEL COMPOUNDS ARG1, IL1B, LTB4R SRC 3928/4885MAPK14 4207/4885MAPK12 3555/4885
US-10000471-B2 Pyrazole P38 map kinase inhibitors MAPK1, MAP3K1, MAPK3 SRC 872/4885MAPK14 31/4885MAPK12 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.